- Home
- BNGO vs VYNE Comparison
BNGO vs VYNE Comparison
Compare BNGO & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- VYNE
- Stock Information
- Founded
- BNGO 2003
- VYNE 2003
- Country
- BNGO United States
- VYNE United States
- Employees
- BNGO N/A
- VYNE N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BNGO Industrials
- VYNE Health Care
- Exchange
- BNGO Nasdaq
- VYNE Nasdaq
- Market Cap
- BNGO 24.3M
- VYNE 24.3M
- IPO Year
- BNGO 2018
- VYNE 2018
- Fundamental
- Price
- BNGO $3.88
- VYNE $0.32
- Analyst Decision
- BNGO Buy
- VYNE Buy
- Analyst Count
- BNGO 5
- VYNE 2
- Target Price
- BNGO $7.67
- VYNE $8.00
- AVG Volume (30 Days)
- BNGO 159.3K
- VYNE 2.0M
- Earning Date
- BNGO 08-14-2025
- VYNE 08-14-2025
- Dividend Yield
- BNGO N/A
- VYNE N/A
- EPS Growth
- BNGO N/A
- VYNE N/A
- EPS
- BNGO N/A
- VYNE N/A
- Revenue
- BNGO $27,426,000.00
- VYNE $476,000.00
- Revenue This Year
- BNGO N/A
- VYNE N/A
- Revenue Next Year
- BNGO $20.81
- VYNE N/A
- P/E Ratio
- BNGO N/A
- VYNE N/A
- Revenue Growth
- BNGO N/A
- VYNE N/A
- 52 Week Low
- BNGO $2.68
- VYNE $0.31
- 52 Week High
- BNGO $30.52
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BNGO 58.90
- VYNE 29.76
- Support Level
- BNGO $3.69
- VYNE $0.32
- Resistance Level
- BNGO $4.38
- VYNE $0.34
- Average True Range (ATR)
- BNGO 0.30
- VYNE 0.02
- MACD
- BNGO 0.05
- VYNE 0.03
- Stochastic Oscillator
- BNGO 64.29
- VYNE 8.52
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.